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Cervical cancer is caused by HPV (human papilloma virus). It is the second 
most common cancer in women living low developed countries. The components 
of cervical cancer prevention and control comprises primary prevention, second-
ary prevention and tertiary prevention. Primary prevention of cervical cancer 
encompasses prevention of infection with HPV. Giving HPV vaccine for girls aged 
9–14 years before they initiate sexual activity is one of the interventions of primary 
prevention of cervical cancer. Screening and treatment is needed in secondary 
prevention of cervical cancer. Screening of cervical cancer encompasses testing a 
target group (women) who are at risk for a cervical pre-cancer. Tertiary preven-
tion of cervical cancer comprises treatment of cervical cancer and palliative care. 
The components of tertiary care comprise surgery, radiotherapy, chemotherapy 
and palliative care. Community mobilization, health education and counseling 
on cervical cancer prevention and control is vital to make ownership on cervical 
prevention. Monitoring and evaluation of cervical cancer prevention and control on 
key program indicators should be done regularly.
Keywords: cervical cancer, primary prevention, secondary prevention, tertiary 
prevention, control, vaccination
1. Introduction
Cervical cancer is caused by sexually acquired infection with certain types 
of HPV (human papilloma virus). HPV is a group of viruses that are extremely 
common worldwide. There are more than 100 types of HPV, of which at least 14 are 
cancer-causing [1]. Worldwide, cervical cancer is the fourth most frequent cancer 
in women. There were 570 000 new cases of cervical in 2018. More than 311 000 
deaths from cervical cancer occur every year. More than 85% of these deaths occur 
in low and middle income countries. Seventy-percent of cervical cancers worldwide 
are caused by only two HPV types (16 and 18) [1, 2].
Abnormal vaginal bleeding is the common symptom of cervical cancer. The 
bleeding can occur after sexual intercourse. Bleeding after menopause or increased 
vaginal discharge may also be symptoms [3].
There are numerous risk factors the can cause cervical cancer. Educational 
status, place of residence, using old sanitary napkins, younger age at marriage, 
sexual transmitted infections, number of partners and health service utilization are 
associated with cervical cancer. Bathing daily and during menstruations is found 
to be preventive factors for cervical cancer [4, 5]. Women who have HIV infection 
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have an increased risk for cervical cancer than women who have no HIV infection 
[3, 6]. Non access to cervical cancer screening, commence sexual intercourse at 
early age, cigarette smoking and long term use of oral contraceptives are also related 
with higher risk of cervical cancer [3, 5]. History of genital warts, immunosuppres-
sion, multiparty, diet low in folates, carotene and vitamin C are also included in risk 
factors of cervical cancer [7].
The component of cervical cancer prevention and control comprise primary, 
secondary and tertiary prevention. Cervical cancer can often be prevented by 
having regular screenings with pap tests and HPV tests to find any pre-cancers and 
treat them. It can also be prevented by receiving the HPV vaccine [8]. World health 
organization (WHO) recommended vaccine that can protect HPV 16 and 18 and 
the vaccine is approved for use in many countries [9]. Avoiding exposure to risk 
factors is additional actions to prevent cervical cancer [8].
WHO put new cervical elimination targets of 90% HPV vaccination coverage, 
70% screening coverage, 90% access to treatment for cervical pre-cancer and 
cancer and access to palliative care by 2030. Attaining these targets can decrease 
more than 40% of new cervical cancer cases and 5 million associated mortality 
by 2050. To achieve this targets efforts should be increased [6]. Availing updated 
evidence based information on cervical cancer prevention and control is important 
to increase the information coverage and to develop best strategies that focus on 
cervical cancer prevention and control. The aim of this chapter is providing the 
best available information on cervical cancer prevention and control. The chapter 
described three components of cervical cancer prevention, community mobiliza-
tion, education and counseling on cervical cancer prevention and monitoring and 
evaluating cervical cancer prevention and control.
2. Prevention and control of cervical cancer
The goal of any comprehensive cervical cancer prevention and control pro-
gramme is to decrease the burden of cervical cancer. This can be done by reducing 
HPV infections, detecting and treating cervical, pre-cancer lesions, and providing 
timely treatment and palliative care for invasive cancer [9].
The key components of comprehensive cervical cancer prevention and control 
contains three interdependent components: primary, secondary and tertiary 
prevention (Figure 1). In Figure 1, programmatic interventions to prevent HPV 
infections and cervical cancer is also illustrated.
Even though, effective cervical cancer methods such as HPV vaccination, 
screening and safe sex practice exists, affordability and putting into practice remain 
challenge for most countries [5].
Unless cervical cancer prevention and control measures are effectively executed, 
it is estimated that by 2030, nearly 800,000 new cases of cervical cancer will be 
annually diagnosed. The huge majority of these cases will be in developing coun-
tries [10]. To reduce this burden, community mobilization, education and counsel-
ing on cervical cancer prevention should be implemented at all levels. Monitoring 
and evaluation of cervical cancer prevention and control on key program indicators 
should also be done on a regular basis.
2.1 Primary prevention of cervical cancer
Prevention of HPV infection is included in primary cervical prevention and 
control. There are different subtypes of HPV that can cause cervical cancer but, the 
major subtypes are 16 and 18 [9].
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The public health goal of primary prevention of cervical cancer is to reduce 
HPV infections. Primary prevention can be realized through behavioral change 
approaches and the use of biological mechanisms, including HPV vaccination. The 
interventions for primary prevention of cervical cancer include: providing immuni-
zation for girls aged 9–14 years before the start sexual intercourse, health education 
on healthy sexuality for both boys and girls and promotion of condom use. HPV 
vaccines are not intended to treat women with past or present HPV infection [9, 11].
The target age group for HPV vaccination is 9–14 years earlier to becoming 
sexual active. Two doses of HPV vaccine with six month interval is required. 
There is no maximum interval between the two doses. But, the interval of not 
greater than 12–15 months is suggested to allow girls to complete the schedule on 
time prior to becoming sexually active. If the interval between doses is shorter 
than 5 months, then a third dose should be offered at least six months after the 
first dose. A three dose schedule (at 0, 1–2, and 6 months) is recommended for 
females 15 years and older and for those known to be immunocompromised  
and/or HIV-infected [10, 12, 13].
It is not essential to screen for HPV infection or HIV infection prior to HPV 
immunization. Pre-immunization assessments (e.g., HPV testing of any kind, 
cervical cancer screening or Pap testing, pregnancy testing, or “virginity testing”) 
are not mandatory [10, 13].
If girls are age ≥ 15 years and received their first dose before age 15 years, they 
may complete the three doses. If no doses were taken before age 15 years, three 
doses should be administered. In both scenarios, immunization can be given up to 
26 years. If adequate resources remain after immunizing girl’s age 9 to 14 years, girls 
who received one dose may take extra doses between age 15 and 26 years. If there 
is ≥50% coverage in the priority female target population, sufficient resources and 
cost effectiveness, boys may be immunized to prevent other non-cervical human 
papillomavirus related cancers and diseases [12].
The HPV vaccines prevent over 95% of HPV infections caused by HPV types 16 
and 18. It may have some cross-protection against other less common HPV types 
which cause cervical cancer [14]. There are three various vaccines, which vary in the 
number of HPV types they comprise and target. However, not all are obtainable in 
everywhere.
Figure 1. 
Programmatic interventions to prevent HPV infections and cervical cancer.
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• Quadrivalent HPV vaccine (Gardasil®) targets HPV types 6, 11, 16 and 18.
• 9-valent vaccine (Gardasil 9®) targets the same HPV types as the quadrivalent 
vaccine as well as types 31, 33, 45, 52 and 58.
• Bivalent vaccine (Cervarix ®) targets HPV types 16 and 18 [5].
Cervarix is the best cost effective vaccine with proved efficacy in one dose. 
The WHO commends two doses for either Gardasil 9 or Cervarix for those up to 
15 years of age and three doses for women 15 years or older. The WHO commends 
are grounded on induced antibody titers at month 7 for Gardasil and Gardasil 9 as 
there are at present no efficacy data for these vaccines in fewer than three doses. The 
WHO recommendations for Cervarix are built on efficacy information in addition 
to immunogenicity information. Three dose efficacy prevents cervical intraepithe-
lial neoplasia (CIN) 2 or worse by any HPV type is around 62% for both Cervarix 
and Gardsail9. The three dose efficacy prevents CIN 3 or worse by any HPV type is 
93% for Cervarix and 43% for Gardasil, with no information for ardasil9 [10, 15] 
(Table 1).
There are numerous HPV vaccination distribution approaches. The followings 
are commonly used distribution approaches:
• Vaccine distribution at health care facilities
• Vaccine distribution through outreach
• Vaccine distribution through campaigns [9, 10, 16].
Educational interventions announcing the risk of HPV and the benefits of 
vaccines are important, especially in low and middle income countries [17]. 
Education and effective communication is vital in attaining successful immuniza-
tion programme [18].
2.2 Secondary prevention of cervical cancer
In secondary prevention of cervical cancer, screening and treatment as desired is 
included. Screening comprises testing women who are at risk for a cervical pre-
cancer. The aim of screening is to detect and treat those people identified as having 
early signs of the illness, usually by means of inexpensive, precise, and reliable test 
that can be practical widely. The other aim of screening is to decrease the death 
related with cervical cancer through identifying the illness when still at an early 
treatable stage or through detecting precursor lesions. The systematic removal of 
CIN lesion during screening also leads to reductions of the incidence of invasive 
cervical cancers of all stages.
There are numerous cervical cancer screening tests in use or being studied 
around the world. Cervical cytology has been in use for the past 50 years. Newer 
screening tests are HPV DNA testing and visual screening tests [19]. Increasing the 
acceptance of screening has many sigfinaces in preventing cervical cancer through 
early detection and treatment of pre-cancerous changes before malignancy grows. 
Approaches of inspiring women to start cervical cancer screening include inviting, 
reminding, teaching, communication framing, counseling, risk factor identification 
and financial interventions. Use of invitations and to a lesser degree educational 
resource are supported by evidence as a good methods of encouraging women to 
undertaken cervical cancer screening [20].
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Screening of cervical cancer is identifying for pre-cancer. Cervical cancer 
screening is recommended for woman aged 30 up to 49 years at least one in life 
time. Early detection and treatment of precancerous lesions can prevent the major-
ity of cervical cancers.
HPV vaccination does not substitute cervical cancer screening. In countries 
where HPV vaccine is introduced, screening programs may need to be developed 
or strengthened [21]. Visual inspection of the cervix without magnification was 
the first technique of screening of the cervix. Nowadays, three types of tests are 
encouraged:

















Disease protection Cervical cancer (and 
premalignant genital lesions 
of cervix, vulva and vagina)
Cervical cancer (and 
premalignant genital lesions 
of cervix, vulva and vagina)
Genital warts
Cervical cancer (and 
premalignant genital 





31, 33 31, 45 Not necessary





0 and 6 months (No 
maximum interval but 
suggested not more than 
12–15 months)
0 and 6 months (No 
maximum interval but 
suggested not more than 
12–15 months)
0 and 6 months (No 
maximum interval 
but suggested 




Intramuscular injection Intramuscular injection Intramuscular 
injection
Presentation and 
Type of Vaccine 
Vial Monitor 
(VVM)
1-dose vial; VVM 30
2-dose vial; VVM 30
1-dose vial; VVM 30 1-dose vial; VVM 
TBD
Shelf-life 48 months at 2–8 °C for 
1-dose vial; 36 months 
at 2–8°C for 2-dose vial; 
vaccine is freeze sensitive
36 months at 2–8°C, vaccine 
is freeze sensitive
36 months at 2–8°C, 
vaccine is freeze 
sensitive
Contraindications Severe allergic reaction to 
any vaccine component 
after first dose
• Severe febrile illness
• Known to be pregnant
Severe allergic reaction to 
any vaccine component after 
first dose
• Severe febrile illness
• Known to be pregnant
Severe allergic 
reaction to any 
vaccine component 
after first dose
• Severe febrile 
illness




Characteristics of HPV vaccines.
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• Conventional Pap smear (or cytology) and liquid-based cytology
• Visual inspection with Acetic Acid (VIA) or with lugol iodine (VILI)
• HPV testing for high risk HPV types (types 16 and 18).
The randomized trial studies done in different places on cervical cancer screen-
ing have shown the efficacy of visual inspection, cytology screening and HPV 
screening [22–24]. Many studies have acknowledged that in countries where the 
resources exist to confirm high value and good coverage of the people, cytology 
screening provides to decreasing the incidence of advanced stage cancers and death 
related with cervical cancer [25–27].
The treatment methods mostly used are cryotherapy, loop electrosurgical  
excision procedure or cold-knife conisation [5].
There are two kinds of HPV tests:
• The test that identify if 13 up to 14 HPV subtypes are present or not. But this 
test cannot help to identify which subtypes are present.
• The tests performed to identify HPV genotyping and identify if HPV 16 or 18 
is present or not.
HIV infected women should undergo cervical cancer screening twice in the first 
year after diagnosis of HIV infection and then annually. For women with two suc-
cessive normal cytological examinations, the recommendation is that annual follow 
up includes a detailed visual inspection of the anus, vulva, and vagina, as well as the 
cervix [5].
Cervical screening based on HPV testing can prevents more invasive cervical 
cancer and precancerous lesions. It can offers innovative options such as self-
collection of specimens to improve screening uptake broadly [28].
2.3 Tertiary prevention of cervical cancer
Tertiary prevention of cervical cancer comprises treatment of cervical cancer 
and palliative care. Surgical treatment, chemotherapy, radiotherapy and palliative 
are included in tertiary cervical cancer prevention [16]. The public health goal of 
tertiary prevention of cervical cancer is to reduce the number of mortality due to 
cervical cancer.
The interventions for tertiary prevention of cervical cancer comprise:
• A referral mechanism from primary care providers to facilities that offer 
cancer diagnosis and treatment
• Accurate and timely cancer diagnosis by exploring the extent of invasion
• Treatment, appropriate to each stage based on the diagnosis [9].
2.4  Community mobilization, education and counseling on cervical cancer 
prevention
Community mobilization is a process of engaging communities and generating 
support for all those in need of health services, resulting in sustainable community 
ownership and involvement. Effective communication can increase rates of vaccination 
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and screening and save women’s lives. Health care workers and others involved in cervi-
cal cancer control at all levels should be trained in basic counseling skills, so that they 
can communicate effectively with clients. The content of the counseling encounter will 
vary according to the client’s problems or concerns and her individual situations. It can 
address prevention, screening, follow-up, referral, diagnosis, treatment of precancer-
ous lesions, treatment of invasive cancer and/or palliative care [9].
2.5 Monitoring and evaluating (M & E) cervical cancer prevention and control
Monitoring and assessing the improvement of objectives and targets at country 
level is crucial. The followings are crucial indicators of cervical cancer preventions 
and control:
• Immunization coverage by year of age and by dose.
• Screening coverage, screening test positivity rate and treatment rate.
• Proportion of curable cancer patients who get adequate treatment and sur-
vival rates.
• Opioid access for women with advanced cervical cancer.
Essential impact indicators of cervical cancer are incidence and death. 
Establishing cancer register is important to monitor the incidence and death rate 
of cervical cancer. The register will help to assess long term impacts of cervical 
cancer screening, treatment and vaccination [21]. The main recording and report-
ing tools that are used for immunization should be adapted to include HPV vaccine. 
The recording and reporting tools comprises: immunization register, tally sheet, 
immunization card, defaulter tracking system, stock record and integrated monthly 
report [10].
M & E helps the management team to determine the extent to which the 
program is meeting the stated goals, objectives, targets and make corrections 
accordingly [16].
An effective program of prevention and control of cervical cancer must address 
several issues, including the coverage and quality of screening services, availability 
of diagnosis, treatment and monitoring [29].
Depending on the country setting and resources available, M & E of cervical 




• Client and community assessment
• Use of new information and communication technology [30].
3. Conclusion
Cervical cancer prevention and control components are primary prevention, 
secondary prevention and tertiary prevention. Primary prevention comprise HPV 
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vaccination of girls 9–14 years old. Secondary prevention include screening and 
treatment with low technology VIA followed by cryotherapy. Tertiary prevention 
of cervical cancer incorporates treatment of invasive cancer and providing pallia-
tive care. Mobilizing community, giving health education and counseling is very 
important in prevention and control of cervical cancer. M & E of cervical cancer 
prevention and control on key program indicators should also be done regularly.
4. Terminology
Bivalent: a vaccine that works by stimulating an immune response against two 
different antigens; e.g. Cervarix is a bivalent vaccine that helps protect the body 
against infection with HPV types 16 and 18.
Chemotherapy: The term that usually describes the use of drugs to treat cancer 
but which may also describe the use of antibiotics to treat infectious diseases.
Cervical intraepithelial neoplasia (CIN): abnormalities in the cells of the 
cervix which may become cancerous.
Cryotherapy: the use of cold or freezing in treatment.
Cytology: the study of individual cells. Cytology’s main use in medicine is to 
detect abnormal cells. It is widely used to screen for cancer (as in the cervical smear 
test) or to confirm a diagnosis of cancer.
DNA (deoxyribonucleic acid): the principal molecule carrying genetic infor-
mation in almost all organisms.
Immunogenicity: the property of eliciting an immune response.
Neoplasia: the pathological process that results in the formation and growth of 
a tumor.
Palliative treatment: treatment that relieves the symptoms of a disorder but 
does not cure it.
Opioid: a type of drug used to relieve strong pain, e.g. morphine.
Quadrivalent: a vaccine that works by stimulating an immune response against 
four different antigens; e.g. Gardasil is a quadrivalent vaccine that helps protect the 
body against infection with HPV types 6, 11, 16 and 18.
Screening: The application of a test to people who are as yet asymptomatic for 
the purpose of classifying them with respect to their likelihood of having a particu-
lar disease. It is not undertaken to diagnose a disease, but to identify individuals 
with increased probability of having either the disease itself or a precursor of the 
disease.
Prognosis: An assessment of the probable course and outcome of a disease.
9
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